Patents by Inventor Roger Pertwee

Roger Pertwee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9669002
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: June 6, 2017
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Roger Pertwee
  • Publication number: 20160220529
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tctrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Application
    Filed: September 11, 2015
    Publication date: August 4, 2016
    Inventors: GEOFFREY GUY, Roger Pertwee
  • Patent number: 9168278
    Abstract: The invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type II diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 27, 2015
    Assignee: GW Pharma Limited
    Inventors: Geoffrey William Guy, Roger Pertwee
  • Publication number: 20100317729
    Abstract: The present invention relates to a novel pharmaceutical formulation comprising a ratioed mix of: (i) one or more compounds that acts as an inverse agonist of the CB1 and/or CB2 receptor; and (ii) one or more compounds that acts as a neutral antagonist of the CB1 and/or CB2 receptor. Preferably both the inverse agonist of the CB1 and/or CB2 receptor and the neutral antagonist of the CB1 and/or CB2 receptor are cannabinoids. Preferably the cannabinoids are tetrahydrocannabidivarin (THCV) and cannabidiol (CBD).
    Type: Application
    Filed: July 4, 2008
    Publication date: December 16, 2010
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Brian Anthony Whittle, Roger Pertwee
  • Publication number: 20100292345
    Abstract: The present invention relates to the use of the cannabinoid cannabigerol (CBG) in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from concurrent agonism of the CBi and the CB2 cannabinoid receptors. Such diseases or conditions to be treated are taken from the group: pain, neurodegenerative disease, ischemic disease, brain injury or damage, acquired brain injury, age related inflammatory or autoimmune disease, cachexia, nausea and vomiting, glaucoma, movement disorders, rheumatoid arthritis, asthma, allergy, psoriasis, Crohn's disease, systemic lupus erythematosus, diabetes, cancer, osteoporosis, renal ischemia and nephritis.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 18, 2010
    Applicant: GW PHARMA LIMITED
    Inventor: Roger Pertwee
  • Publication number: 20100286098
    Abstract: The present invention relates to the use of a substantially pure tetrahydrocannabinol (THC) or a THC containing extract in which THC is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. A further embodiment of the invention relates to the use of a substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid, in the manufacture of a medicament for use in the treatment of an inflammatory bowel disease. Additionally the substantially pure cannabidiol (CBD) or a CBD containing extract in which CBD is a primary cannabinoid are used in the manufacture of a medicament for use as an adjunct therapy in the treatment of an inflammatory bowel disease.
    Type: Application
    Filed: June 25, 2008
    Publication date: November 11, 2010
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Roger Pertwee, Joanna Jamontt
  • Publication number: 20090306221
    Abstract: The present invention relates to the use of one or more cannabinoids in the manufacture of medicaments for use in 0 the treatment of diseases and conditions benefiting from inverse agonism of the CB1 and/or the CB2 cannabinoid receptor. Preferably the cannabinoid is a cannabidiol (CBD) type compound or derivative thereof.
    Type: Application
    Filed: May 31, 2007
    Publication date: December 10, 2009
    Applicant: GW PHARMA LIMITED
    Inventors: Geoffrey Guy, Roger Pertwee, Adele Thomas
  • Publication number: 20080119544
    Abstract: The invention relates to the use of one or more cannabinolds in the manufacture of medicaments for use in the treatment of diseases and conditions benefiting from neutral antagonism of the CB, cannabinoid receptor. Preferably the cannabinoid is tetrahydrocannabivarin (THCV). Preferably the diseases and conditions to be treated are taken from the group: obesity, schizophrenia, epilepsy, cognitive disorders such as Alzheimer's, bone disorders, bulimia, obesity associated with type n diabetes (non-insulin dependant diabetes) and in the treatment of drug, alcohol and nicotine abuse or dependency.
    Type: Application
    Filed: November 15, 2005
    Publication date: May 22, 2008
    Applicant: GW PHARMA LIMITED
    Inventors: Geoffrey William Guy, Roger Pertwee
  • Publication number: 20050096379
    Abstract: Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.
    Type: Application
    Filed: June 24, 2003
    Publication date: May 5, 2005
    Inventors: Billy Martin, Raj Razdan, Roger Pertwee